| Bioactivity | PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo[1][2]. |
| Target | IC50: 20 nM (Autotaxin, in mouse plasma) IC90: 200 nM (Autotaxin, in mouse plasma) |
| Name | PAT-048 |
| CAS | 1359983-15-5 |
| Formula | C22H18ClF2N3O2S |
| Molar Mass | 461.91 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Castelino FV, et al. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheumatol. 2016 Dec;68(12):2964-2974. [2]. Black KE, et al. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB J. 2016 Jun;30(6):2435-50. |
PAT-048
CAS: 1359983-15-5 F: C22H18ClF2N3O2S W: 461.91
PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.